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Abstract
Background: Patent ductus arteriosus (PDA) is one of most common complications in preterm infants. Although
ibuprofen represents the first choice for the closure of PDA, this treatment can cause severe gastrointestinal and
adverse renal effects and worsen platelet function. The successful closure of the PDA with paracetamol has been
recently reported in several preterm infants, and the safety of paracetamol for this use has been suggested by the
available data.
Methods/design: We present the design of a randomized, multicenter, controlled study, whose aim is to assess the
effectiveness and safety of intravenous paracetamol in comparison to intravenous ibuprofen for the treatment of
PDA in preterm infants. A total of 110 infants born at 25+0 to 31+6 weeks of gestational age will be enrolled and
randomized to receive paracetamol or ibuprofen (55 patients per group) starting at 24–72 h of life. The primary
endpoint of the study is the comparison of the PDA closing rate observed after a 3-day course with paracetamol
or ibuprofen. The secondary endpoints include the closure rate of PDA after the second course of treatment with
ibuprofen, the re-opening rate of the PDA, the incidence of surgical ligation, and the occurrence of adverse effects.
Discussion: The results of this study will provide new information about the possible use of paracetamol in the
treatment of PDA. Paracetamol could offer several important therapeutic advantages over current treatment
options, and it could become the treatment of choice for the management of PDA, mainly due to its more
favorable side effect profile.
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Introduction
Background and rationale
The patency of ductus arteriosus is a frequent complica-
tion in preterm infants suffering from respiratory dis-
tress syndrome (RDS), and 60 to 70 % of preterm infants
at <28 weeks of gestation receive medical or surgical
therapy for a PDA [1]. Neonates with a left-to-right
shunt through the ductus complicating their RDS have a
higher respiratory failure; lower survival rate; and an in-
creased risk of intraventricular hemorrhage (IVH), bronch-
opulmonary dysplasia (BPD), and necrotizing enterocolitis
(NEC) [2]. Therefore, closure of the PDA is indicated be-
fore a significant left-to-right shunting occurs.
The current treatment of PDA encompasses two steps:
the first is its pharmacological treatment with a nonste-
roidal anti-inflammatory drug (NSAID), and the second,
in case of medical treatment failure, is surgical ligation,
which should be avoided if possible because of the associ-
ated severe complications [3]. Standard medical therapy
for PDA closure mainly involves either indomethacin or
ibuprofen. Both are successful in promoting ductal closure
in 70–80 % of cases [2, 4, 5]. However, these drugs can
cause severe adverse effects involving the gastrointestinal
apparatus, kidney function, and platelet aggregation,
thereby inducing the development of gastrointestinal per-
forations, acute renal failure, and bleeding disorders [6–9].
Therefore, although ibuprofen appears to be the drug of
choice at present for PDA pharmacological closure be-
cause it shows fewer side effects compared to indometh-
acin [4], it does not represent the ideal drug because of its
sub-optimal safety profile [4, 10, 11] and because of its ap-
proximately 30 % failure rate [8–10]. Some concerns have
been raised about a possible increased risk of hyperbiliru-
binemia in ibuprofen-treated infants due to its displace-
ment property of bilirubin from albumin [7], although this
effect has not been confirmed [12].
Thus, the pharmacological treatment of PDA remains
troublesome [1], and to reduce the occurrence of ad-
verse effects and the need for surgical closure advances
in this field should pursue the objective of identifying
other drugs suitable for preterm infants that are safer
and more effective than ibuprofen.
The successful closure of PDA with paracetamol has
been recently reported in several preterm infants, with-
out signs of toxicity [13–22]. A total of 74 preterm neo-
nates with PDA have been treated with paracetamol
(oral or intravenous), with closure being obtained in 66
(89 %) neonates without the development of adverse ef-
fects (Table 1) [13–22]. Two randomized, single-center,
controlled studies compared the effectiveness and safety
of oral paracetamol to ibuprofen for the treatment of
PDA in preterm infants [23, 24]. Both studies
Table 1 Case series of infants treated with paracetamol for patent ductus arteriosus (PDA)
Author Year Number
of patients
GA
(weeks)
BW (g) Postnatal age
(days)
Daily dosage/
administration route
No. of PDA
closure
Safety issues
Hammerman
2012 [13]
5 26–32 720–1210 3–35 60 mg/kg oral 5/5 No toxicity observed.
Oncel
2013 [14]
8 27–34 630–2970 5–27 60 mg/kg oral 7/8 Pre-treatment and post-treatment
liver enzymes were normal
in all patients.
Oncel
2013 [15]
10 24–30 590–990 2–15 60 mg/kg intravenous 10/10 No adverse effects were observed.
Pre-treatment and post-treatment
liver enzymes were normal
in all patients.
Yurttutan
2013 [16]
6 26–33 920–1600 3–7 60 mg/kg oral 5/6 No adverse side effects were observed.
Pre-treatment and post-treatment liver
enzymes and bilirubin were normal
in all patients.
Ozdemir
2013 [17]
7 23–32 620–1615 20–47 60 mg/kg oral 5/7 No side effects, no hepatotoxicity,
and no abnormalities in the
hematologic and biochemical analyses.
Sinha 2013 [18] 10 27–33 800–1380 4–7 45 mg/kg oral 10/10 No side effects related to paracetamol.
Jasani
2013 [19]
6 28–31 1040–1235 2–8 60 mg/kg oral 6/6 No adverse effects. Pre-treatment and
post-treatment liver enzymes were
normal in all neonates.
Kessel
2014 [20]
7 26–30 789–1322 not available 60 mg/kg oral 7/7 No side effects related to paracetamol.
Terrin
2014 [21]
8 24–28 551–897 38–94 h 60 mg/kg intravenous 6/8 No side effects related to paracetamol.
Nadir 2014 [22] 7 24–27 656–951 2–22 60 mg/kg oral 5/7 No abnormalities in hematologic and
biochemical analyses.
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demonstrated that the paracetamol PDA closure rate
was similar to that of the ibuprofen (81.2 versus 78.8 %
[23] and 72.5 versus 77.5 % [24], respectively). Moreover,
Dang et al. [23] found a lower rate of gastrointestinal
bleeding and hyperbilirubinemia in the paracetamol than
in the ibuprofen group, but these findings were not con-
firmed by Oncel et al. [24] (Table 2). Interestingly, only
two case series [15, 21] have reported the successful ef-
fect of intravenous paracetamol for closing PDA in 18
preterm infants. We believe that this point may be very
relevant because the intravenous route is certainly more
suitable than the enteral route in the preterm infant,
whose enteral drug absorption is often uncertain or and
who frequently develops feeding intolerance and thus can-
not be treated with oral drugs. Therefore, a demonstration
that intravenous paracetamol is effective in the closure of
PDA could benefit many patients.
Presumably, the beneficial effect of paracetamol in
the closure of PDA is mediated through the ability of
paracetamol to inhibit in vivo prostaglandin synthesis
[25]. Traditional nonsteroidal anti-inflammatory drugs
(NSAIDs) compete with the arachidonic acid substrate
for the active site of the cyclooxygenase (COX) subunit
of Prostaglandin H synthase, block access to the sub-
strate, and, thereby, reduce the levels of prostaglandin
production. The potency of the NSAIDs is therefore
influenced by the amount of endogenous substrate
present. Once the arachidonic acid has gained access
to the active site, however, these drugs will have no
further inhibitory effect. Paracetamol also inhibits
prostaglandin G/H synthase (PGHS) activity, although
the precise mechanism of its action remains controversial.
It has been proposed that paracetamol does not access the
active site of the enzyme, but rather acts on the peroxidase
(POX) segment of the enzyme [26]. Thus, whereas COX
is dependent on arachidonic acid concentrations, POX
can function at low arachidonic acid levels. On the other
hand, POX is activated at tenfold lower peroxide concen-
trations than COX [27, 28]. In principle, these differences
would permit POX to operate under conditions where
COX is not activated [29]. Under conditions in which
the local peroxide concentrations are low, paracetamol-
mediated inhibition of PGHS may be facilitated. As a
result, the paracetamol might be expected to be max-
imally effective under conditions of hypoxia, which, in
turn, might be associated with low peroxide levels. In
other words, paracetamol is, in theory, ideally situated
for treatment in the environment that facilitates patency
of the ductus arteriosus. Alternatively, paracetamol has
been proposed to selectively inhibit a distinct, less well-
known, central isoform of cyclooxygenase (COX-3) [30].
This theory has generally been rejected for several reasons
[31], and the very existence of a functional human COX-3
has been questioned. In fact, the interactions between
paracetamol and cyclooxygenase remain somewhat vague
and complex in nature.
Objectives
The present study has been designed to assess the efficacy
and safety of intravenous paracetamol in comparison to
Table 2 Randomized controlled trials comparing the effectiveness of oral paracetamol to oral ibuprofen in closing patent ductus
arteriosus (PDA)
Author Year Number of patients GA (weeks) Mean postnatal age Treatment dosage Results
Dang 2013 [23] 160 ≤ 34 ≤ 14 days Paracetamol: 15 mg/kg every
6 h for 3 days
Overall, PDA closure occurred in 65 patients
(81.2 %) in the paracetamol group and in
63 patients (78.8 %) in the ibuprofen
group (P = 0.693).
Ibuprofen: 10 mg/kg followed
by 5 mg/kg after 24 and 48 h
The rate of gastrointestinal bleeding and
hyperbilirubinemia was significantly higher
in the ibuprofen group with respect to the
paracetamol group (P < 0.05). No significant
differences were found for other major
adverse events.
Oncel 2014 [24] 90 ≤ 30 48–96 h Paracetamol: 15 mg/kg every
6 h for 3 days
After the first treatment course, the PDA
closed in 29 (72.5 %) patients enrolled
in the paracetamol group versus 31
(77.5 %) patients assigned to the ibuprofen
group (P = 0.6). The cumulative closure
rates after the second treatment course
were high in both groups: only 1 patient
(2.5 %) in the paracetamol group and
2 patients (5 %) in the ibuprofen group
required surgical ligation.
Ibuprofen: 10 mg/kg followed
by 5 mg/kg after 24 and 48 h
Bilirubin and liver enzyme levels before
and after each treatment course were
not significantly different between groups.
No patient showed oliguria.
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intravenous ibuprofen for the treatment of PDA in pre-
term infants.
Trial design
This is a randomized, open-label, parallel-group, ibuprofen-
controlled, multicenter, prospective study, involving five
Neonatal Intensive Care Units (NICU) in Italy. The
trial was designed following the SPIRIT 2013 statement
(see Additional file 1). The study was planned as a nonin-
feriority trial. A total of 110 patients are expected to be
enrolled in the study and to be randomized to either the
paracetamol or ibuprofen group (55 patients per group).
Informed parental consent will be obtained before en-
rollment. Patients who meet the inclusion criteria will
start the 3-day course of investigational treatment
within 24–72 h of age. If PDA closure is achieved, the
patients will receive follow-up examinations; if PDA is
still open and not hemodynamically significant, patients
will be monitored daily for the next 3 days and, then,
will receive follow-up examinations; if PDA is still open
and hemodynamically significant, patients in both the
groups will be treated with a 3-day course of ibuprofen
as a rescue medication. In case of further failure of
pharmacological treatment, the management of PDA
(i.e., further pharmacological and/or surgical treatment)
will be performed following the hospital’s local protocol.
The full plan of examinations is detailed in the “Interven-
tions” section. The study flowchart is illustrated in Fig. 1.
The duration of the study will be 12 months. The trial
will terminate when the last recruited infant performs
the last follow-up examination scheduled by the protocol.
The study protocol was conceived in October 2013, and
approval by the local ethical committees was completed in
2014. However, recruitment could not begin due to the
temporary shortage of Pedea® on the market. Recruitment
is expected to start by the end of 2015 and to be com-
pleted by the beginning of 2017.
Methods/design
Study setting
The study will take place at five Italian NICUs in
Academic Hospitals. The participating centers are listed
below:
– Neonatal intensive Care Unit, Division of
Neonatology, Careggi University Hospital of
Florence, Largo Brambilla 3, 50134 Firenze, Italy
– Neonatal Intensive Care Unit, Division of
Neonatology, Fondazione IRCCS “Ca’ Granda”
University Hospital, Via Della Commenda 12, 20122
Milano, Italy
– Neonatal Intensive Care Unit, “V. Buzzi” Children
Hospital of Milan, Via Castelvetro 22, 20154
Milan, Italy
– Neonatal Intensive Care Unit, Division of
Neonatology, G. Gaslini Children's University
Hospital of Genova, Via Gerolamo Gaslini 5,
16147 Genova, Italy
– Neonatal Intensive Care Unit, Division of
Neonatology, “A. Gemelli” University Hospital,
Largo Agostino Gemelli 8, 00168 Roma, Italy
Eligibility criteria
Inclusion criteria
Inborn infants satisfying the following inclusion criteria
will be eligible to participate in the study:
Fig. 1 Study procedures flowchart
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1. Born at 25+0 to –31+6 weeks of gestation (and)
2. Parental consent has been obtained (and)
3. Echocardiographic evidence of hemodynamically
significant PDA between the first 24 and 72 h of life.
The diagnosis of hemodynamically significant PDA
will be made by echocardiographic demonstration of
a ductal left-to-right shunt, with a left atrium-to-
aortic root ratio >1.3 or a ductal size >1.5 mm, with
those cases in which the closing flow pattern
suggests a restrictive PDA being excluded [32, 33].
Exclusion criteria
Patients meeting any of the following exclusion criteria
will not be eligible to participate in the study:
1. Major congenital malformations and disorders.
2. Fetal hydrops.
3. Life-threatening infection, defined as positive blood
culture sample at birth.
4. Echocardiographic evidence of pulmonary
hypertension diagnosed when the presence of a
right-to-left shunt through the foramen ovale or
ductus arteriosus is demonstrated, or the estimated
pulmonary pressure from the tricuspid regurgitation
jet is more than two-thirds the systemic arterial
pressure.
5. Grade 3 or 4 IVH.
6. Serum creatinine concentration >1.5 mg/dl
(132 μmol/l).
7. Urine output <1 ml/kg/h during a 24-h collection
period or urine output <0.5 ml/kg/h during the first
24 h of life.
8. Platelet count <50,000/mm3.
9. Major bleeding, as revealed by hematuria, or blood
in the endotracheal aspirate, gastric aspirate,
or stools, or consistent blood oozing from
puncture sites.
10.Severe liver failure, defined as elevated liver
enzymes (ALT/GPT and AST/GOT) >2 times the
upper boundary of the normal range. For this kind
of population, the following ranges are considered
normal: ALT/GPT: 6–50 U/L and AST/GOT:
35–140 U/L [34].
11.Participation in another trial involving any
investigational drug.
12.Previous treatment with paracetamol, ibuprofen,
or any COX inhibitor, for any purpose.
Interventions
The study medications will be an intravenous solution
(10 mg/ml) of paracetamol (Tachipirina®, Angelini
S.p.A., Ancona, Italy) versus an intravenous solution
(5 mg/ml) of ibuprofen (Pedea®, Orphan Europe,
Puteaux la Defense, France). Patients will be randomly
allocated to one of the following treatment groups:
– Group I patients will receive paracetamol
intravenous solution, 15 mg/kg per dose
(corresponding to 1.5 ml/kg) every 6 h for 3 days,
for a total of 12 doses. Paracetamol will be
administered in accordance with the clinical
practice for the management of pain relief in the
newborn [35, 36].
– Group II patients will receive ibuprofen intravenous
solution at an initial dose of 10 mg/kg, followed by
5 mg/kg after 24 and 48 h. Pedea® has been selected
as the comparator treatment because it represents
the only drug authorized in Europe since 2004 for
the treatment of a PDA in preterm newborn infants
<34 weeks of gestational age. The ibuprofen doses
are consistent with those reported in the relevant
Summary of Product Characteristics.
Both intravenous drugs will be infused continuously
over a period of 15–30 min.
The dose of 15 mg/kg for IV paracetamol was chosen
based on previously reported data for paracetamol in the
treatment of PDA in preterm newborns, although lower
doses are also reported in this population for pain-control
purposes [37, 38]. All reported case series of paracetamol
for PDA closure was administered orally or intravenously,
15 mg/kg every 6 h for 3 to 7 days [39–44]. No adverse
effects related to the drug were reported [39–44], even in
patients treated with long courses of paracetamol for 6–7
days [42–44], thus receiving twice as much or more of the
total amount of drug than our population. Pharmacokinet-
ics of paracetamol has been poorly investigated so far in
preterm newborns. Data from pharmacokinetic studies of
paracetamol in the analgesia of preterm newborns were
recently included in a population pharmacokinetic ana-
lysis [45]. Using a three-compartment structural model
for distribution and elimination of the drug, the authors
demonstrated that dosage ranges from 11 to 13 mg/kg per
dose were appropriate for newborns of 500–2000 g [45].
Moreover, plasma paracetamol concentrations were also
measured in one recent study investigating paracetamol
for PDA closure [43]. Patients received 15 mg/kg every
6 h for 3 days, and the plasma paracetamol concentration
assessed before the fifth and ninth doses and 24 h after
treatment termination did not exceed those recommended
for analgesia in infants.
Compliance will be defined as full adherence to the
protocol. Compliance with the protocol will be ensured
by a number of procedures included in the site set-up.
The local principal investigator participated in the pre-
paratory meetings in which details of the study protocol
and data collection were accurately discussed. All centers
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received detailed instruction on study procedures and
web-based recording data, and contact will be possible for
the sponsor study manager or the appointed CRO, which
is delegated by the sponsor to perform monitoring activity,
to resolve possible difficulties. During the trial, the investi-
gational centers will be periodically contacted by the des-
ignated clinical monitor, who will perform on-site visits in
order to verify that the trial is conducted in accordance
with the protocol, Good Clinical Practice, and all ap-
plicable regulatory requirements.
Daily clinical care of the enrolled patients will be per-
formed by the attending physicians in accordance with
the common practice at each center. Daily fluid intake
will be started at 70–80 ml/kg and gradually increased
by 10–20 ml/kg/day on the basis of changes in body
weight, serum sodium concentrations, and osmolality,
with a target intake of 150–160 ml/kg at the end of the
first week of life. In case of hypotension refractory to the
fluid-replacement therapy, dopamine and/or dobutamine
treatment will be provided. For the treatment of RDS,
infants will receive oxygen therapy, respiratory support,
and rescue surfactant treatment in order to achieve
the following therapeutic targets: PaO2 50–60 mmHg,
PaCO2 < 65 mmHg, pH > 7.20, and SpO2 90–95 %. In-
fants will be fed with maternal and/or human milk
and/or preterm formula from the first day of life as
minimal enteral feeding or for nutritional purposes at
the discretion of the physician on duty. For cases in
which the infusion of a glucose solution is clinically
indicated, the concentration will be chosen in order to
maintain an appropriate level of glycemia. In patients with
a central venous line or weighing <1500 g (regardless of
the type of venous access), amino acids will be adminis-
tered from the first hour of life, and fat, no later than at
2 days of life. Prophylactic antibiotics will be administered
from the time of admission to the NICU and will be
stopped after 3–4 days if the results of the bacterial cul-
tures remain negative.
During the study, the use of other NSAIDs will not be
allowed for any purposes, and concomitant medications
and adverse events will be recorded in the patient’s elec-
tronic Case Report Form (eCRF).
Outcomes
Primary outcome measurements
The primary endpoint of the study will be the success
rate in closing the PDA using paracetamol in compari-
son to ibuprofen after the first course of treatment.
Secondary outcome measurements
Secondary outcome measurements will include the
following:
1. Closure rate of PDA after the first and second
day of the first treatment course
2. Closure rate of PDA after the second course of
treatment with ibuprofen
3. Re-opening rate of PDA
4. Incidence of surgical ligation
5. Incidence of renal failure, liver failure, and
gastrointestinal complications (NEC and isolated
perforation) within 30 days. For study purposes,
the renal failure is defined as a serum creatinine
concentration >1.5 mg/dl (132 μmol/l) and urine
output <1 ml/kg/h during a 24-h collection period.
Liver failure is defined as elevated liver enzymes
more than two times the upper boundary of the
normal range (normal ranges: ALT/GPT = 6–50 U/L
and AST/GOT = 35–140 U/L) [34].
Further collected data
The following data will be recorded for each infant: ges-
tational age (GA); birth weight (BW); birth length; birth
cranial circumference; sex; mode of delivery; Apgar score
at 5 min; main maternal pathologies; antenatal steroid
treatment; vital signs; the highest FiO2 and mean airway
pressure values; need and duration of noninvasive airway
pressure ((nasal continuous airway pressure (NCPAP), bi-
phasic positive airway pressure (BiPAP), nasal intermittent
mandatory ventilation (N-IMV), and humidified high flow
nasal cannula (HHFNC)) and invasive ventilation respira-
tory support ((patient-triggered ventilation (PTV), includ-
ing synchronized intermittent positive pressure ventilation
(SIPPV), synchronized intermittent mandatory ventilation
(SIMV), pressure support ventilation (PSV), or high fre-
quency oscillatory ventilation (HFOV)); the need for
surfactant treatment; daily fluid intake; urine output; con-
comitant diseases; concomitant treatments; and adverse
events.
We will also report the occurrence of sepsis, IVH,
periventricular leukomalacia (PVL), BPD, retinopathy of
prematurity (ROP), NEC, length of stay in the neonatal
intensive care unit (NICU) and hospital, and mortality.
A diagnosis of sepsis will be based on clinical and la-
boratory data (white cell count, C-reactive protein con-
centration) and will be confirmed by positive blood
cultures [46]. IVH will be graded according to a standard
classification system [47]. A diagnosis of PVL will be
made when cystic areas are detected by cerebral ultra-
sonography at 40 weeks post-conception birth [48]. BPD
will be defined as the oxygen requirement at 36 weeks
post-conception [49]. ROP will be graded according to
the international classification of retinopathy of prema-
turity [50]. NEC will be diagnosed in agreement with
classical Bell’s criteria [51]. Patients will be discharged
from the NICU to a lower level of care when they no
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longer need respiratory assistance other than oxygen-
therapy and central venous catheters.
Participant timeline
The patients enrolled in the trial will receive a maximum
of 12 clinical examinations: the screening exam from
birth up to 24 h of life; the exam 0 at 24–72 h of life
(before starting pharmacological treatment); exams 1, 2,
3, 4, 5, and 6 carried out 1, 2, 3, 4, 5, and 6 days after
the exam 0; follow-up exams at 7 (±1), 15 (± 2), and 30
(± 2) days after the exam 0; and at 40 weeks of post-
conception. A heart ultrasound will be performed at
screening and exam 0 to rule out ductal-dependent
congenital heart diseases and pulmonary hypertension
and to evaluate the PDA. In enrolled patients, echocar-
diography will be repeated every 24 h during the first
and second treatment course and 24 h after the last
dose of the treatment. The echocardiography will be re-
peated at the first three follow-up exams and in case of
clinically suspected PDA re-opening. If, at exam 3, the
echocardiogram indicates a nonhemodynamically sig-
nificant PDA, further daily echocardiographic evalu-
ation will be performed for the next 3 days. In cases of
PDA, the ductal size and the left-atrium-to-aortic-root
ratio will be recorded at each heart ultrasound.
Cardiac ultrasound will be performed by expert per-
sonnel, specifically a pediatric cardiologist or a neonat-
ologist who has achieved adequate expertise in newborn
heart ultrasound, fulfilling the current recommendations
for echocardiography training in the NICU (45). The
personnel in charge of cardiac ultrasound will be blind
to the randomization arm of the patient for the entire
duration of the study period.
Serial cerebral ultrasounds for evidence of possible
IVH and/or PVL will be performed at the screening; at
the exams 0, 3, and 6; at the follow-up exams 7 (± 1), 15
(± 2), and 30 (± 2) days after exam 0; and at 40 weeks
post-conception.
Laboratory tests will be performed at the screening; at
exams 3 and 6; and at the follow-up exams 7 (± 1) and
30 (± 2) days after exam 0. Clinical laboratory tests will
include the count of red blood cells, white blood cells,
and platelets and the serum value measurements of
hemoglobin/hematocrit, creatinine, urea nitrogen, total
bilirubin, total proteins, liver enzymes, sodium, potas-
sium, and calcium. The laboratory test will be performed
on a 1-ml blood sample, obtained by heel, venous, or ar-
terial puncture. Urine output will be monitored during the
study by weighing nappies or by urethral catheterization if
clinically indicated, beginning with the screening visit.
The schedule of the investigational drug administra-
tion is summarized in Fig. 2, whereas the visits and
exams are summarized in Fig. 3.
Sample size
The study was conceived as a superiority trial aimed to
demonstrate the superiority of paracetamol over ibupro-
fen on the primary efficacy endpoint of closing PDA
after a 3-day course. Assuming a 25 % ibuprofen failure
rate in closing PDA [52] and a 5 % paracetamol failure
rate (improvement of 20 %), we used the χ2 test to calcu-
late that a sample size of 49 evaluable patients per group
will be necessary to determine a statistically significant
decrease of 20 % in the failure rate in the paracetamol
group at a two-sided alpha level of 5 % and with a power
of 80 %. The sample size was calculated with the NQuery
Advisor® software 7.0 and SAS® PROC POWER. Hypothe-
sizing a 10 % drop-out rate of patients who will not
complete the first 3-day course of treatment, we
planned to enroll 55 infants in each group; thus, 6 more
infants were needed for each group, as calculated with
N = n/(1−d).
The assumption of a 95 % efficacy of paracetamol was
based on previously reported data on the effectiveness of
paracetamol in the treatment of hsPDA, ranging from
71 % [17] to 100 % [13, 18–20]. Specifically, the lowest
observed efficacy of 71 % was observed in a cohort of
newborns who received oral paracetamol after a double-
course ibuprofen failure [17], whereas an efficacy of
100 % was reported in four case series [13, 18–20] and
of 83–88 % in three case series [14–16]. Overall, despite
the high heterogeneity of the reported cases, paraceta-
mol was effective in 93 % (55/59) of the treated infants.
The following populations are defined for statistical ana-
lysis: the modified intention-to-treat (m-ITT) population
is includes all randomized patients who have completed
Fig. 2 Participant treatment timeline
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the first treatment course and have undergone baseline
and day 3 echocardiographic assessment; the per protocol
(PP) population includes patients from the m-ITT popula-
tion who have no major protocol violations; and the safety
population (SP) includes all patients who take at least one
dose of study medication.
Recruitment
Before patients are entered into the study, the parents
(or legal representatives) will be fully informed about the
purposes of the study, possible benefits, any potential
reasonable risk or discomfort, the expected duration of
the newborn’s participation, the clinical and/or func-
tional procedures, as well as the name of the investiga-
tor(s) responsible for conducting the trial and his/her
direct contact details. Written and oral information will
be offered to parents, and sufficient time will be allowed
for consent. The newborn will enter the study only after
both parents or legal representatives sign the informed
consent form. A senior investigator will be available at
all times to discuss concerns raised by parents or clini-
cians during the course of the trial.
A monthly accrual report about the study will be sent
to participating centers.
An estimated 680 infants of gestational age 25+0 to
31+6 weeks will be born during the 12-month period at
the participating centers: 160 at the Florence Site, 160
at the Rome site, 160 at the Milan site (Ospedale Maggiore
Policlinico of Milan), 100 at the Genoa site, and 100 at the
Milan site (“V. Buzzi” Children Hospital of Milan). Of the
270 remaining infants, we assume that 25 % would not be
enrolled due to PPHN, major malformations, or the ab-
sence of parental consent, thereby resulting in 216 eligible
patients. Therefore, no major problems of enrollment
completion are expected, as the expected eligible popula-
tion definitely exceeds the number of patients who must
be enrolled.
Assignment of interventions
Sequence generation
Infants at each unit will be randomly assigned in blocks
to a treatment group (paracetamol or ibuprofen) in a 1:1
ratio. The allocation sequences consist of computer-
generated random numbers.
Since the frequency of the PDA is inversely related
to gestational age (GA), the inclusion of patients will
be balanced in each treatment group according to the
following gestational ages: 250 to 27+6 weeks or 28+0 to
31+6 weeks.
Fig. 3 Participant visit timeline. 1Visit 0 has to be performed at 24–72 h of age. Visit 0 and the screening visit can be performed in the same day
starting at 24 h of life. 2 Visit 4, Visit 5, and Visit 6 have to be performed in case the echocardiography highlights a non-hsPDA (Outcome 2) or a
persistent hsPDA (Outcome 3) at Visit 3. 3 Follow-up visits (F-up 1, F-up 2, F-up 3, and F-up 4) have to be performed only by patients with an
ongoing presentation of Outcome 1 and Outcome 2 at Visit 3. 4 The following parameters will be recorded: ductal size and the left-atrium-to-aortic-root
ratio. 5 At Visit 3, in accordance with the echocardiographic evaluation, patients will be differentiated in the following: Outcome 1: patients presenting
closed PDA. Outcome 2: patients with non-hsPDA. Outcome 3: patients with persistent hsPDA. 6 Procedures applicable only for patients undergoing the
second treatment course of ibuprofen as rescue medication. 7 Laboratory analyses: hematology (including RBC, WBC, platelets, hemoglobin,
and hematocrit), creatinine, blood urea nitrogen, AST/GOT, ALT/GPT, total bilirubin, total protein, sodium, potassium, and calcium
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Allocation concealment
The enrolled patients will be allocated to the treatment
arm using automatically generated, sealed, opaque labels,
which will be provided to each participating center by
the sponsor to ensure the allocation concealment. Pa-
tient enrollment and allocation to treatment will be the
responsibility of the neonatologists involved in the study
at the different participating centers.
Blinding
As the primary endpoint (PDA closure) is objectively de-
tected by echocardiography and cannot be affected by
the open label-condition, the study will not be blinded.
However, the personnel in charge of the cardiac ultra-
sound will be blinded to the randomization arm of the
patient for the entire duration of the study period. On
the other hand, the open-label design is necessary because
the different dose schedule of paracetamol and ibuprofen
makes the double-blind design inapplicable. However, to
minimize bias, strict criteria and definitions for hsPDA
will be maintained during the trial.
Data collection methods
All collected data will be obtained from the clinical re-
cords at each clinical examination scheduled by the proto-
col, as summarized in Fig. 3. No duplicate measurement
strategy for laboratory tests will be applied; this will
minimize the volume of the blood samples, as the enrolled
population will consist of very preterm newborns who
would be exposed to a consistent risk of iatrogenic anemia
in case of repeated samples. Cardiac ultrasound will be
performed by expert personnel, specifically a pediatric car-
diologist or a neonatologist who has achieved adequate
expertise in newborn heart ultrasound, having fulfilled the
current recommendations for echocardiography training
in the NICU [25]. Data collection forms are included in
the eCRF that was specifically designed for the trial.
The data for patients discontinuing the study will be
collected as summarized in Fig. 3.
Data management
All the collected data will be recorded by the local in-
vestigator on a web-based eCRF that was specifically
designed for this study by Angelini S.p.A. using SAS
PheedIt system. SAS PheedIt is a fully validated web-based
application that is compliant with the FDA 21CFR11 and
European regulations regarding electronic records and sig-
natures. Data entry screens have been created to capture
the clinical data required per protocol. Only authorized
site personnel with an assigned personal account and
password will have access to the eCRF. Subjects will be
identified by sex, birth date, and assigned trial number
only, in accordance with personal data protection law.
All study data captured in the study database will be
(1) verified against original data records by the clinical
monitor during on-site monitoring visits and (2) subjected
to quality control and referred back to the relevant center
for clarification in the event of inconsistency, missing
items, or uncertainty.
The study coordinator and trial statistician will review
the generated results for logic, coherence, or problems.
Outlier data will be investigated.
Statistical methods
An analysis of the primary and secondary endpoints of
the study will be carried out on the m-ITT and PP popu-
lations. The clinical characteristics of the infants in the
paracetamol and ibuprofen groups will be described
using mean value and standard deviation, median value
and range, or frequencies and percentage. Univariate
statistical analysis will be performed using the Student t
test for parametric continuous variables, the Wilcoxon
rank-sum test for nonparametric continuous variables,
and the χ-square test for categorical variables. A P < 0.05
will be considered statistically significant. The type of
treatment, clinical characteristics that are most likely
associated with the occurrence of PDA refractory to
pharmacological closure (i.e., gestational age, birth
weight, antenatal steroids, mechanical ventilation, etc.),
and variables that will be significantly different between
groups (P < 0.100) will be included in the multiple lo-
gistic regression analysis to assess their independent
roles in predicting the closure of PDA. Effect estimates
will be expressed as the relative risk (RR) with profile
likelihood-based 95 % confidence limits.
Safety and tolerability assessments will be carried out
on the SP population.
Missing data
In order to prevent a large amount of missing data, the
follow-up period for the primary outcome of ductal closure
was established in the short term for 30 days, whereas the
follow-up period was conceived to finish at 40 weeks of
gestation, when the enrolled patients are likely to be still
admitted to the hospital. The personnel involved in the
study will be selected based on their expertise in a previous
clinical trial, and all the investigators and study staff will be
trained on the importance of the completion of the study
period of enrolled patients. Parents will also be informed
about this crucial aspect to reduce dropout, and a senior
investigator will be available at each site anytime the
parents may need further information or clarification
during the study period.
Data monitoring
Data will be monitored by personnel from the “Mediola-
num Cardio Research”, Via Carducci 19, 20123 Milan, a
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society offering support for clinical trials, which is inde-
pendent from the sponsor.
No interim analyses are scheduled per protocol. The
decision to terminate the trial is the responsibility of
the sponsor and of the principal investigators of the co-
ordinating center.
Harms
Safety and tolerability will be assessed by monitoring the
frequency and severity of adverse events. Changes from
baseline in the physical examination, vital signs, and
urine output will be also assessed. Laboratory analyses
will be evaluated on the basis of the normal ranges, the
investigator’s judgment, and the mean changes from
screening.
All adverse events, both nonserious and serious, whether
treatment related or not, or expected or unexpected, will
be recorded during the clinical trial, starting from receipt
of the signature of informed consent to the last follow-up
examination scheduled at 40 weeks post-conception age.
All serious adverse events will be transmitted in a timely
manner (within 24 h from initiation) by the investigator to
the sponsor, who is responsible for the relevant notification
to all applicable competent authorities in accordance with
pharmacovigilance regulations.
Ethics and dissemination
Research ethics approval
The study protocol was conceived in October 2013 in ac-
cordance with the European Community Guidelines of
Good Clinical Practice for Trials on Medicinal Products
and the “Declaration of Helsinki” (World Medical Assem-
bly in 1964 and following revisions). The study was ap-
proved by the Italian competent authority AIFA (Agenzia
Italiana del Farmaco) and by the local ethical committees of
the participating centers: the Pediatric Ethical Committee
of Tuscany, Ethical Committee of Milan-B Area, Ethical
Committee of Milan-C Area, Ethical Committee of Liguria
and Ethical Committee of the Catholic University of the
Sacred Heart of Rome.
Protocol amendment during the study period, if any,
will be submitted for approval to all the aforementioned
ethical committees.
Consent
Before patients are entered into the study, the parents
(or legal representatives) will be fully informed about the
purposes of the study, possible benefits, any potential
reasonable risk or discomfort, the expected duration of
the newborn’s participation, the clinical and/or func-
tional procedures, as well as the name of investigator(s)
responsible for conducting the trial and his/her direct
contact details. Written and oral information will be of-
fered to the parents, and sufficient time will be allowed
for consent. The consent will be obtained by the neona-
tologists involved in the trial at the different participat-
ing centers. A senior investigator or a junior investigator
with a senior supervisor will be in charge of obtaining
the consent.
Confidentiality
Only authorized site personnel will be authorized to
collect patient data for the study purposes and will have
access to the eCRF with an assigned personal account
and password. Subjects will be identified by sex, birth
date, and assigned trial number, during and after the
trial, in accordance with personal data protection law.
Access to data
The principal investigators of each site and the sponsor
will have complete access to the final trial dataset, and
no contractual agreement exists to limit such access for
the investigators.
Dissemination policy
The results of the trial are expected to be published in a sci-
entific journal and to be presented in medical seminars and
conferences. The final reporting will follow the CONSORT
Report guidelines (http://www.consort-statement.org).
Discussion
Recent results reported on the use of paracetamol in the
treatment of PDA are highly promising, but adequately
powered, randomized controlled clinical trials are needed
to validate these promising observations. The aim of this
study is to collect consistent data on the efficacy and
safety of intravenous paracetamol, in comparison to ibu-
profen, for the treatment of PDA in preterm infants.
The proper timing of the pharmacological treatment
of hsPDA in preterm newborns is still a matter of de-
bate, and the clinical practice widely varies among differ-
ent centers [53]; early treatment may have a beneficial
impact on early PDA-related morbility, whereas late de-
layed treatment prevents overtreatment in those cases of
spontaneously closing PDA [54]. Recent data suggest
that early ibuprofen treatment of hsPDA at a median
age of 3 days does not significantly affect the occurrence
of BPD, death, BPD or death, NEC, severe IVH and
PVL, in comparison with delayed treatment at median
age of 11 days in newborn of 23–32 weeks of gestation,
suggesting that late treatment is safe and more favorable
in terms of overtreatment reduction [54]. It has been re-
ported that 49 % of all PDA spontaneously close within
the first week in newborns with birthweight <1500 g and
in 94 % of newborns prior to discharge, suggesting that
deferring treatment decisions until at least 1 week of life
may avoid unnecessary treatment exposure [55]. In a co-
hort of newborns <27 weeks of gestational age, treated
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with an early (0–2 days), intermediate (3–6 days), or late
(≥ 7 days) start, the timing of PDA treatment was not
associated with a risk of PDA surgery or death [56].
However, only 31 % of infants with a birthweight
<1000 g presented spontaneous closure within 1 week
[55], and in a cohort of preterm newborns treated with
mixed timing of initiation, newborns who experienced
failed PDA closure with indomethacin showed signifi-
cantly delayed treatment initiation in comparison to
newborns with successful closure, and newborns treated
on day 5 presented a significantly higher failure rate in
comparison to those treated on day 3, suggesting that
later initiation of treatment may decrease the success
rate [57]. Moreover, a randomized controlled trial of
very early treatment of PDA within the first 12 h of life
in newborns <29 weeks of gestation demonstrated that
newborns who received early indomethacin had a lower
occurrence of early pulmonary hemorrhage and a trend
toward less IVH in comparison to the placebo group,
although no differences were detected in the death rate
[58]. In fact, very early pharmacological prophylaxis
regimens of PDA are still in use, at least in very pre-
term babies [59].
Paracetamol could offer several important therapeutic
advantages over current treatment options, considering
that in the neonatal population, it appears well tolerated
when used at the analgesic dosing regimen commonly
administered in NICU [35]. Finally, paracetamol could
become the treatment of choice for the management of
hemodynamically significant PDA, mainly due to its
more favorable side effect profile. As the participating
centers’ practices consists of early treatment of hsPDA
during the first 24–72 h of life, any positive results of
our study may need to be confirmed in clinics using a
late treatment approach before paracetamol may be con-
sidered for hsPDA closure independently of the timing
of treatment.
Trial status
Patient enrollment began in December 2015 in one center
and in January 2016 in the remaining center.
Additional file
Additional file 1: The SPIRIT 2013 Statement recommendations for
clinical trial protocols. (DOCX 50 kb)
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